Tempus reported a 36% year-over-year jump in Q1 revenue and raised full-year guidance, supported by growth in its diagnostics business and higher minimal residual disease (MRD) testing volume. The company’s quarterly diagnostics performance drove revenue to $348.1 million. On the commercial metrics, Tempus said MRD test volume grew to about 6,500 tests, roughly sixfold year over year, while oncology volumes increased 28%. The company also cited hereditary testing growth, alongside continued expansion of its data and modeling revenue. Tempus used the results to reinforce platform momentum: it highlighted multi-year collaborations, including a strategic agreement with Merck to accelerate biomarker discovery and an expanded collaboration with Gilead for enterprise-wide access to its Lens platform. The quarter also included higher R&D and SG&A expenses, but Tempus delivered a smaller-than-expected non-GAAP loss per share, bolstering investor confidence that scaling diagnostics and analytics can translate into durable financial performance.